P450 inhibitors of use in medical treatment: focus on mechanisms of action.
A number of cytochrome P450s are targets for compounds that are clinically used or under clinical evaluation for treatment of patients with mycotic infections, such as dermatophytosis, superficial and systemic candidiasis, cryptococcosis and aspergillosis, with skin diseases, such as psoriasis or ichthyosis, and other retinoid-sensitive malignancies, e.g., neuro-ectodermal glioma. Some of the P450 inhibitors are candidates for the treatment of hirsutism or prostate cancer, others are potent inhibitors of the P450 isomerase involved in the synthesis of thromboxane A2, a potent platelet aggregation inducer and vasoconstrictor.
D000728:Androgens / Q000138:chemical synthesis; D000818:Animals; D000935:Antifungal Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D002177:Candidiasis; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects / Q000378:metabolism; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008958:Models, Molecular; D009181:Mycoses / Q000150:complications / Q000188:drug therapy*; D013261:Sterols / Q000096:biosynthesis; D013329:Structure-Activity Relationship; D013931:Thromboxanes / Q000138:chemical synthesis; D014212:Tretinoin / Q000378:metabolism
D000728:Androgens; D000935:Antifungal Agents; D065607:Cytochrome P-450 Enzyme Inhibitors; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors; D013261:Sterols; D013931:Thromboxanes; D014212:Tretinoin; D003577:Cytochrome P-450 Enzyme System